Medical ReviewPolicy

Pages are candidates for medical review when they discuss prescription treatments, dosing, contraindications, side effects, treatment eligibility, safety monitoring, or clinically sensitive comparisons.

This usually includes medication guides, safety pages, side effect articles, treatment program explanations, and content that could affect how a reader evaluates risks or next steps in care.

Medical review focuses on factual accuracy, completeness of safety context, appropriate clinical caveats, and whether patient-facing language could be misunderstood as personal medical advice.

Reviewers may assess statements about eligibility, adverse effects, contraindications, dose escalation, monitoring, expected results, care pathways, and language describing pharmacies or providers.

Trimi's named clinical reviewer is Dr. Asad Niazi, MD, MPH, a licensed physician and Master of Public Health practicing through the Beluga Health 50-state telemedicine network. Dr. Niazi reviews patient eligibility for compounded GLP-1 weight management therapy and clinical content on this site that addresses prescription treatment, dosing, contraindications, side effects, or safety monitoring.

Beluga Health serves as Trimi's clinical infrastructure partner — a multistate medical service organization (MSO) that maintains state-by-state physician licensure and credentialing across the 50 US states. When a patient's state falls outside Dr. Niazi's individual licensure, another credentialed Beluga physician handles the intake under the same clinical protocols described on this page.

Prescriptions are dispensed by Trimi's named 503A community sterile compounding pharmacy partners: VialsRx (Texas State Board pharmacy license #35264, which fulfills the majority of Trimi prescriptions) and GreenwichRx. Both pharmacies are FDA-overseen and operate under current Good Manufacturing Practice (cGMP) standards for sterile preparation of patient-specific prescriptions.

Eligibility review aligns with FDA labeling thresholds for the active ingredients used in Trimi's compounded formulations — generally BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity such as type 2 diabetes, hypertension, dyslipidemia, sleep apnea, or established cardiovascular disease.

Content review references the Endocrine Society's 2024 Clinical Practice Guideline on pharmacological management of obesity in adults, the American Association of Clinical Endocrinology (AACE) Comprehensive Type 2 Diabetes Management Algorithm 2024, and the prescribing information for the brand-name finished products containing the same active ingredients (semaglutide in Wegovy and Ozempic; tirzepatide in Mounjaro and Zepbound).

Contraindication screening includes personal or family history of medullary thyroid carcinoma (MTC), Multiple Endocrine Neoplasia type 2 (MEN 2) syndrome, history of pancreatitis, severe gastrointestinal disease, severe renal impairment, current pregnancy or breastfeeding, and prior serious hypersensitivity reaction to GLP-1 receptor agonists.

Some pages display medical review details directly through badges, review dates, or reviewer callouts. Those signals are meant to help readers understand that the content received an added clinical accuracy pass.

Some operational or organization-level pages may be reviewed at the program level without a named reviewer card on every page. In those cases, Trimi may use a team-based medical review attribution rather than a single named reviewer.

In all cases, a medically reviewed page should still be read as general education rather than personalized care instructions.

We revisit medical content when there are meaningful updates to treatment safety information, prescribing guidance, regulatory context, site offerings, or patient support workflows.

Content may also be re-reviewed during scheduled refresh cycles, when editorial teams flag clinical ambiguity, or when readers report a possible issue that requires confirmation.

Medical review does not replace a direct evaluation by a licensed clinician. It does not confirm that any specific treatment is appropriate for any particular patient, and it should not be used as a substitute for urgent or emergency care.

A patient-provider relationship begins only through the appropriate clinical intake and review process, not by reading site content alone.